Summary
- Current Price
- As of today, ASND price is $240.65, up +1.39% on
- Current Price All-Time High
- ASND price is currently -3.20% below its historical high of $248.60 set on
- Market Cap
- ASND current market cap is $15B, up +62.16% over the past 365 days
- PE Ratio
- ASND PE ratio is unknown
- Revenue
- ASND current annual revenue is $812.73M, up +106.62% year-over-year
- Next Earnings
- The next earnings release for ASND is on
Profile
| Metric | Value |
|---|---|
| Full Name | Ascendis Pharma A/S |
| Ticker | NASDAQ: ASND |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Denmark |
| IPO | |
| Indexes | Not included |
| Website | ascendispharma.com |
| Employees | 1,017 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $240.65 | |
| Price, 1D Change | +1.39% | |
| Market Cap | $15B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.21 | |
| Revenue | $813M | |
| Revenue, 1Y Change | +106.62% | |
| EPS | -$4.25 | |
| EPS, 1Y Change | +39.89% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$4.25 | |
| EPS Estimate | N/A | $4.65 |
| EPS Est. Change | N/A | +209.55% |
| Revenue | $812.73M | |
| Revenue Estimate | N/A | $1.40B |
| Revenue Est. Change | N/A | +72.25% |
| Current Price | $240.65 | |
| Price Target | - | - |
| Price Tgt. Change | - | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$6.59 | -$7.06 | -7.26% | |
| -$3.33 | -$4.25 | -27.57% | |
| $4.65 | N/A | +209.55% | |
| $11.01 | N/A | +359.28% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $321.31M | $393.35M | +22.42% | |
| $719.78M | $812.73M | +12.91% | |
| $1.40B | N/A | +72.25% | |
| $1.99B | N/A | +144.54% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +58.83% | |
| Price, 3Y | +111.91% | |
| Market Cap, 1Y | +62.16% | |
| Market Cap, 3Y | +126.55% | |
| Revenue, 1Y | +106.62% | |
| Revenue, 3Y | +1,411.13% | |
| EPS, 1Y | +39.89% | |
| EPS, 3Y | +61.15% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $240.65 | |
| SMA 200 | $198.79 | |
| SMA 200 vs Price | -17.40% | |
| SMA 50 | $222.10 | |
| SMA 50 vs Price | -7.71% | |
| Beta | 0.21 | |
| ATR | $10.10 | |
| 14-Day RSI | 60.56 | |
| 10-Day Volatility | 36.68% | |
| 1-Year Volatility | 38.59% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $812.73M | |
| EPS | -$4.25 | |
| Gross Profit | $691.49M | |
| Gross Margin | 85.08% | |
| Operating Profit | -$153.79M | |
| Operating Margin | -18.92% | |
| Net Income | -$257.35M | |
| Net Margin | -31.67% | |
| EBITDA | -$133.82M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | -5.35 | |
| 1.04 | ||
| 0.76 | ||
| - | ||
| 3 | ||
| 2.46 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 17.86 | ||
| -76.89 | ||
| -119.69 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | -$191.22M | |
| $723.51M | ||
| $1.53B | ||
| $1.30B | ||
| $1.72B | ||
| $1.26B | ||
| Total Debt | $1.02B | |
| $571.41M | ||
| $106.47M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $1.07B | ||
| $845.29M | ||
| $121.23M | ||
| $516.74M | ||
| $19.97M | ||
| $0.00 | ||
| $17.36M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| $60.83M | ||
| -$9.58M | ||
| $41.00M | ||
| Capex | $9.58M | |
| $51.25M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wedbush | → | |
| Oppenheimer | → | |
| B of A Securities | → | |
| Barclays | ||
| Wells Fargo | → | |
| RBC Capital | → | |
| Wells Fargo | → | |
| TD Cowen | → | |
| Stifel | → | |
| Wedbush | → |
Analyst sentiment
Institutional ownership
Screeners with ASND
FAQ
What is the ticker symbol for Ascendis Pharma A/S?
The ticker symbol for Ascendis Pharma A/S is NASDAQ:ASND
Does Ascendis Pharma A/S pay dividends?
No, Ascendis Pharma A/S does not pay dividends
What sector is Ascendis Pharma A/S in?
Ascendis Pharma A/S is in the Healthcare sector
What industry is Ascendis Pharma A/S in?
Ascendis Pharma A/S is in the Biotechnology industry
What country is Ascendis Pharma A/S based in?
Ascendis Pharma A/S is headquartered in Denmark
When did Ascendis Pharma A/S go public?
Ascendis Pharma A/S initial public offering (IPO) was on January 28, 2015
Is Ascendis Pharma A/S in the S&P 500?
No, Ascendis Pharma A/S is not included in the S&P 500 index
Is Ascendis Pharma A/S in the NASDAQ 100?
No, Ascendis Pharma A/S is not included in the NASDAQ 100 index
Is Ascendis Pharma A/S in the Dow Jones?
No, Ascendis Pharma A/S is not included in the Dow Jones index
When was Ascendis Pharma A/S last earnings report?
Ascendis Pharma A/S's most recent earnings report was on February 11, 2026
When does Ascendis Pharma A/S report earnings?
The next expected earnings date for Ascendis Pharma A/S is April 30, 2026
Data Sources & References
- ASND Official Website ascendispharma.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1612042/000119312526046590/0001193125-26-046590-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1612042/000119312526046590/0001193125-26-046590-index.htm
- ASND Profile on Yahoo Finance finance.yahoo.com/quote/ASND
- ASND Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/asnd